Evidence-based recommendations for antimicrobial nasal washes in chronic rhinosinusitis

American Journal of Rhinology

Volumn 20, Issue 1, 2006, Pages 1-6

  Elliott, Kimberly A ^a   Stringer, Scott P ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BETA LACTAM; CEFTAZIDIME; CLINDAMYCIN; LEVOFLOXACIN; OFLOXACIN; PSEUDOMONIC ACID; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BURNING SENSATION; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; COUGHING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRY SKIN; ERADICATION THERAPY; EVIDENCE BASED PRACTICE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOSE IRRITATION; NOSE SURGERY; OTALGIA; PRACTICE GUIDELINE; PRURITUS; REVIEW; RHINOSINUSITIS; SORE THROAT; STANDARDIZATION; TREATMENT FAILURE;

EID: 33645235443     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.1177/194589240602000101     Document Type: Review

References (39)

1. Kaliner MA, Osguthorpe JD, Fireman P, et al. Sinusitis: Bench to Bedside. J Allergy Clin Immunol. 99:S829-S848, 1997.
2. Westrin KM, Stierna P, Kumlien J, et al. Induction, course, and recovery of maxillary sinusitis: A bacteriological and histological study in rabbits. Am J Rhinol 4:61-64, 1990.
3. Ponikau JU, Sherris DA, Kita H, et al. Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J Allergy Clin Immunol 110:862-866, 2002.
4. Leonard DW, and Bolger WE. Topical antibiotic therapy for recalcitrant sinusitis. Laryngoscope 109:668-670, 1999.
5. Rosenfeld M, Gibson R, McNamara S, et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 129: 572-577, 2001.
6. Elledge ES, Whiddon RG Jr, Fraker JT, et al. The effects of topical oral clindamycin antibiotic rinses on the bacterial content of saliva on healthy human subjects. Otolaryngol Head Neck Surg 105:836-839, 1991.
7. Grandis Jr, Vickers RM, Rihs JD, et al. The efficacy of topical antibiotic prophylaxis for contaminated head and neck surgery. Laryngoscope 104:719-724, 1994.
8. Nadel DM, Lanza DC, and Kennedy DW. Endoscopically guided cultures in chronic rhinosinusitis. Am J Rhinol 12: 233-341, 1998.
9. Sonnenburger RE, Coffey CS, Dubin MG, et al. Endoscopically guided cultures in post-surgical patients with chronic rhinosinusitis. Presented at the Combined Otolaryngology Spring Meeting of The Triological Society, Phoenix, May 2004.
10. Vellucci A, Marcucci L, Greco D, et al. Use of ceftazidime in the treatment of otorhinolaryngoiatric bacterial infections. Int J Clin Pharmacol Ther Toxicol 25:282-288, 1987.
11. Slocombe B, and Perry C. The antimicrobial activity of mupirocin-an update on resistance. J Hosp Infect 19:19-25, 1991.
12. Sutherland R, Boon RJ, Griffin KE, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 27:495-498, 1985.
13. Bertino JS. Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 54: 2185-2191, 1997.
14. Hill RL. The bioavailability of mupirocin in nasal secretions in vitro. J Clin Pathol 55:233-235, 2002.
15. Chapnick EK, Gradon JD, Kreiswirth B, et al. Comparative killing kinetics of methicillin-resistant Staphylococcus aureus by bacitracin or mupirocin. Infect Control Hosp Epidemiol 17:178-180, 1996.
16. Miller TR, Muntz HR, Gilbert ME, et al. Comparison of topical medication delivery systems after sinus surgery. Laryngoscope 114:201-204, 2004.
17. Olson DE, Rasgon BM, and Hilsinger RL Jr. Radiographic comparison of three methods for nasal saline irrigation. Laryngoscope 112:1394-1398, 2002.
18. National Center for Health Statistics. Vital Health Stat 10: 199, 1995.
19. Talbot AR, Herr TM, and Parsons DS. Mucociliary clearance and buffered hypertonic saline solution. Laryngoscope 107: 500-503, 1997.
20. Boek WM, Keles, N, Graamans K, et al. Physiologic and hypertonic saline solutions impair ciliary activity in vitro. Laryngoscope 109:396-399, 1999.
21. Unal M, Gorur K, and Ozcan C. Ringer-Lactate solution versus isotonic saline solution on mucociliary function after nasal septal surgery. J Laryngol Otol 115:796-797, 2001.
22. Keojampa BK, Nguyen MH, and Ryan MW. Effects of buffered saline solution on nasal mucociliary clearance and nasal airway patency. Otolaryngol Head Neck Surg 131:679-682, 2004.
23. Scheinberg PA, and Otsuji A. Nebulized antibiotics for the treatment of acute exacerbations of chronic rhinosinusitis. Ear Nose Throat J 81:648-652, 2002.
24. Vaughan WC, and Carvalho G. Use of nebulized antibiotics for acute infections in chronic sinusitis. Otolaryngol Head Neck Surg 127:558-568, 2002.
25. Saijo R, Majima Y, Hyo N, et al. Particle deposition of therapeutic aerosols in the nose and paranasal sinuses after transnasal sinus surgery: A cast model study. Am J Rhinol 18:1-7, 2004.
26. Heatley DG, McConnell KE, Kille TL, et al. Nasal irrigation for the alleviation of sinonasal symptoms. Otolaryngol Head Neck Surg 125:44-48, 2001.
27. Tamooka LT, Murphy C, and Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 110: 1189-1193, 2000.
28. Moss RB, and King VK. Management of sinusitis in cystic fibrosis by endoscopic surgery and serial antimicrobial lavage. Arch Otolaryngol Head Neck Surg 121:566-572, 1995.
29. Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 7(suppl 1):S13-S20, 2003.
30. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis; 2004. Otolaryngol Head Neck Surg130:1-45, 2004.
31. Turnidge JD. The pharmacodynamics of B-lactams. Clin Infect Dis 27:10-22, 1998.
32. Craig WA, and Ebert SC. Killing and regrowth of bacteria in vitro: A review. Scand J Infect Dis Suppl 74:63-70, 1991.
33. Preston SL. The importance of appropriate antimicrobial dosing: Pharmacokinetic and pharmacodynamic considerations. Ann Pharmacother 38:S14-S18, 2004.
34. Forrest A, Nix DE, and Ballow CH. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073-1081, 1993.
35. Casewell MW, and Hill RL. Elimination of nasal carriage of staphylococcus aureus with mupirocin - A controlled trial. J Antimicrob Chemother 17:365-372, 1986.
36. Fernandez C, Gaspar C, Torrellas A, et al. A double-blind, randomized, placebo-conrolled trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 35:399-408, 1995.
37. Doebbeling BN, Breneman DL, Neu HC, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: Analysis of six clinical trials with calcium mupirocin ointment. Clin Infect Dis 17:466-474, 1993.
38. Solares CA, Batra PS, Hall GS, et al. Treatment of chronic rhinosinusitis exacerbations due to methicilling-resistant Staphylococcus aureus with mupirocin irrigations. Presented at the Combined Otolaryngology Spring Meeting of The Triological Society, Phoenix, May 2004.
39. Gosepath J, Grebneva N, Mossikhin S, et al. Topical antibiotic, antifungal, and antiseptic solutions decrease ciliary activity in nasal respiratory cells. Am J Rhinol 16:25-31, 2002.